US7563874B2
(en)
|
1998-08-31 |
2009-07-21 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
CN100480260C
(en)
|
2002-07-18 |
2009-04-22 |
克鲁塞尔荷兰公司 |
Recombinant production of mixtures of antibodies
|
EP2374819B1
(en)
|
2003-05-12 |
2017-03-22 |
Helion Biotech ApS |
Antibodies to MASP-2
|
SG188175A1
(en)
|
2004-06-03 |
2013-03-28 |
Novimmune Sa |
Anti-cd3 antibodies and methods of use thereof
|
US8663634B2
(en)
*
|
2005-07-11 |
2014-03-04 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
SG174779A1
(en)
*
|
2005-09-12 |
2011-10-28 |
Novimmune Sa |
Anti-cd3 antibody formulations
|
ES2856451T3
(en)
|
2005-10-11 |
2021-09-27 |
Amgen Res Munich Gmbh |
Compositions comprising specific antibodies for different species, and uses thereof
|
JP5144499B2
(en)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
Antibody modification method for purifying bispecific antibodies
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
JP2009539841A
(en)
*
|
2006-06-06 |
2009-11-19 |
トラークス,インコーポレイテッド |
Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
|
EP2037961B1
(en)
|
2006-06-14 |
2015-11-11 |
MacroGenics, Inc. |
Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
|
EP2094302A4
(en)
*
|
2006-12-21 |
2010-12-08 |
Macrogenics Inc |
Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
|
US7883705B2
(en)
*
|
2007-02-14 |
2011-02-08 |
Kyowa Hakko Kirin Co., Ltd. |
Anti FGF23 antibody and a pharmaceutical composition comprising the same
|
CA2680741A1
(en)
|
2007-03-22 |
2009-01-15 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
US20100183615A1
(en)
*
|
2007-04-03 |
2010-07-22 |
Micromet Ag |
Cross-species-specific bispecific binders
|
EP4059964A1
(en)
*
|
2007-04-03 |
2022-09-21 |
Amgen Research (Munich) GmbH |
Cross-species-specific binding domain
|
JP2010524851A
(en)
*
|
2007-04-03 |
2010-07-22 |
マイクロメット アーゲー |
Species-specific binding domains
|
US8999337B2
(en)
*
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
EP2209485B1
(en)
*
|
2007-11-06 |
2016-03-30 |
Oklahoma Medical Research Foundation |
Extracellular histones as biomarkers for prognosis and molecular targets for therapy
|
RU2502800C2
(en)
*
|
2008-01-15 |
2013-12-27 |
Эббви Инк. |
Improved expression vectors of mammals and their use
|
EP2313434A4
(en)
|
2008-07-31 |
2013-03-27 |
Univ California |
Antibodies that neutralize botulinum neurotoxins
|
SG193216A1
(en)
|
2008-08-18 |
2013-09-30 |
Amgen Fremont Inc |
Antibodies to ccr2
|
MX338038B
(en)
*
|
2008-10-01 |
2016-03-30 |
Amgen Res Munich Gmbh |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody.
|
US10981998B2
(en)
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
CA2738565C
(en)
|
2008-10-01 |
2023-10-10 |
Micromet Ag |
Cross-species-specific psmaxcd3 bispecific single chain antibody
|
WO2010041145A2
(en)
|
2008-10-07 |
2010-04-15 |
Novimmune Sa |
Il-17-mediated transfection methods
|
WO2010132872A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Novimmune S.A |
Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US8926976B2
(en)
*
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
WO2011053743A1
(en)
*
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
TWI653333B
(en)
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
Cross-species specific PSMAxCD3 bispecific single chain antibody
|
JP6082344B2
(en)
*
|
2010-05-27 |
2017-02-15 |
ゲンマブ エー/エス |
Monoclonal antibody against HER2 epitope
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
JP6055763B2
(en)
|
2010-06-16 |
2016-12-27 |
トレリス バイオサイエンス リミテッド ライアビリティー カンパニー |
High affinity human antibody against human cytomegalovirus (CMV) gB protein
|
DK3029066T3
(en)
|
2010-07-29 |
2019-05-20 |
Xencor Inc |
ANTIBODIES WITH MODIFIED ISOELECTRIC ITEMS
|
CN103154025B
(en)
*
|
2010-08-02 |
2015-07-01 |
宏观基因有限公司 |
Covalent diabodies and uses thereof
|
MX341579B
(en)
|
2010-08-03 |
2016-08-25 |
Abbvie Inc * |
Dual variable domain immunoglobulins and uses thereof.
|
KR101767860B1
(en)
|
2010-08-20 |
2017-08-14 |
와이어쓰 엘엘씨 |
Designer osteogenic proteins
|
US9688735B2
(en)
|
2010-08-20 |
2017-06-27 |
Wyeth Llc |
Designer osteogenic proteins
|
AU2011293253B2
(en)
|
2010-08-26 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2012047427A2
(en)
|
2010-08-31 |
2012-04-12 |
The Regents Of The University Of California |
Antibodies for botulinum neurotoxins
|
WO2012064792A2
(en)
*
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
US11066483B2
(en)
|
2010-11-30 |
2021-07-20 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
US9249217B2
(en)
|
2010-12-03 |
2016-02-02 |
Secretary, DHHS |
Bispecific EGFRvIII x CD3 antibody engaging molecules
|
US20120189621A1
(en)
*
|
2011-01-21 |
2012-07-26 |
Yann Dean |
Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
|
JP2014515598A
(en)
|
2011-03-10 |
2014-07-03 |
エイチシーオー アンティボディ, インク. |
Bispecific three-chain antibody-like molecule
|
BR112013021562B1
(en)
|
2011-03-16 |
2023-01-10 |
Argenx Bvba |
ANTIBODIES TO CD70
|
US20140170149A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
CN103842383B
(en)
*
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
Polyspecific FAB fusion proteins and its application method
|
SI2714733T1
(en)
|
2011-05-21 |
2019-06-28 |
Macrogenics, Inc. |
Cd3-binding molecules capable of binding to human and non-human cd3
|
WO2012173819A2
(en)
*
|
2011-06-14 |
2012-12-20 |
Mayo Foundation For Medical Education And Research |
Anti-cd3 therapies
|
BR112013032217B1
(en)
*
|
2011-06-17 |
2021-01-19 |
Novo Nordisk A/S |
use of an anti-nkg2a antibody
|
CN103781801B
(en)
*
|
2011-08-23 |
2018-02-09 |
罗切格利卡特公司 |
Include the antibody and application method without Fc of two Fab fragments
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
KR102398736B1
(en)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
CA2861610A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
NZ772318A
(en)
|
2012-04-20 |
2023-06-30 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
CA2876133C
(en)
*
|
2012-06-07 |
2017-06-06 |
Duke University |
Human bispecific egfrviii antibody engaging molecules
|
KR101566538B1
(en)
*
|
2012-06-08 |
2015-11-05 |
국립암센터 |
Novel epitope for switching to Th17 cell and use thereof
|
WO2014006217A1
(en)
|
2012-07-06 |
2014-01-09 |
Genmab B.V. |
Dimeric protein with triple mutations
|
JOP20200236A1
(en)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
|
DK2900694T3
(en)
|
2012-09-27 |
2018-11-19 |
Merus Nv |
BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
|
TW202210507A
(en)
|
2012-11-01 |
2022-03-16 |
美商艾伯維有限公司 |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014110601A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
TWI682941B
(en)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
Antibodies comprising chimeric constant domains
|
US9062108B2
(en)
|
2013-03-15 |
2015-06-23 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 and/or IL-17
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
CN104098698B
(en)
*
|
2013-04-08 |
2019-04-05 |
中国人民解放军第二军医大学 |
A kind of anti-cd 3 antibodies and its preparation method and application
|
DK2989203T3
(en)
*
|
2013-04-23 |
2020-02-17 |
The Univ Court Of The Univ Of Aberdeen |
SYNTHETIC LIBRARY FOR SPECIFIC BINDING MOLECULES
|
PL3019532T3
(en)
*
|
2013-07-09 |
2019-10-31 |
Univ Duke |
Human bispecific egfrviii antibody engaging molecules
|
CA2920368C
(en)
*
|
2013-07-23 |
2023-03-21 |
Centro De Inmunologia Molecular |
Use of a cd6 binding partner and method based thereon
|
US20150174242A1
(en)
|
2013-12-19 |
2015-06-25 |
Mayo Foundation For Medical Education And Research |
Monovalent anti-cd3 adjuvants
|
US10844127B2
(en)
|
2014-02-28 |
2020-11-24 |
Merus N.V. |
Antibodies that bind EGFR and ErbB3
|
IL301147A
(en)
|
2014-02-28 |
2023-05-01 |
Merus Nv |
Antibody that binds erbb-2 and erbb-3
|
TWI701042B
(en)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
Methods and antibody compositions for tumor treatment
|
CR20160506A
(en)
|
2014-03-28 |
2017-03-10 |
Xencor Inc |
Bispecific Antibodies that bind to CD38 and CD3
|
CA2943943C
(en)
|
2014-04-07 |
2023-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
SG11201609417VA
(en)
*
|
2014-04-10 |
2016-12-29 |
Stichting Vumc |
IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS
|
MX2016014434A
(en)
*
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
T cell-redirected antigen-binding molecule for cells having immunosuppression function.
|
SG11201609950YA
(en)
*
|
2014-05-28 |
2016-12-29 |
Hoffmann La Roche |
Antibodies binding to human and cynomolgus cd3 epsilon
|
JP2017520575A
(en)
|
2014-07-01 |
2017-07-27 |
ファイザー・インク |
Bispecific heterodimeric diabody and uses thereof
|
JP6871155B2
(en)
|
2014-07-25 |
2021-05-12 |
メモリアル スローン ケタリング キャンサー センター |
Bispecific HER2 and CD3 binding molecules
|
US11820832B2
(en)
|
2014-07-25 |
2023-11-21 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
US10391168B1
(en)
|
2014-08-22 |
2019-08-27 |
University Of Bern |
Anti-CD70 combination therapy
|
MA40764A
(en)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT INDUCING CYTOTOXICITY
|
CA2967820A1
(en)
|
2014-11-17 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using cd3xcd20 bispecific antibody
|
JP7146397B2
(en)
*
|
2014-11-17 |
2022-10-04 |
アディセット バイオ, インコーポレイテッド |
Engineered γδ T cells
|
DK3223845T3
(en)
|
2014-11-26 |
2021-08-16 |
Xencor Inc |
HETERODIMERING ANTIBODIES BINDING CD3 AND CD20
|
CA2968878A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
ES2717308T3
(en)
|
2014-12-06 |
2019-06-20 |
Gemoab Monoclonals Gmbh |
Pluri- or multi-potent genetically modified stem cells and their uses
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
CN114230667A
(en)
|
2015-01-23 |
2022-03-25 |
赛诺菲 |
anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
CA2981312C
(en)
|
2015-03-30 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
WO2016180468A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Biontech Cell & Gene Therapies Gmbh |
Claudin-18.2-specific immunoreceptors and t cell epitopes
|
AU2016259792B2
(en)
*
|
2015-05-13 |
2019-07-25 |
Ablynx N.V. |
T cell recruiting polypeptides based on TCR alpha/beta reactivity
|
TW201710286A
(en)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
Binding proteins against VEGF, PDGF, and/or their receptors
|
EP3115376B1
(en)
|
2015-07-10 |
2018-09-05 |
Merus N.V. |
Human cd3 binding antibody
|
IL307276A
(en)
|
2015-08-28 |
2023-11-01 |
Amunix Operating Inc |
Chimeric polypeptide assembly and methods of making and using the same
|
LT3365373T
(en)
|
2015-10-23 |
2021-05-25 |
Merus N.V. |
Binding molecules that inhibit cancer growth
|
CA3003969A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
WO2017086367A1
(en)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
CN108699136B
(en)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
Heterodimeric antibodies that bind CD3 and PSMA
|
KR20180085740A
(en)
|
2015-12-09 |
2018-07-27 |
에프. 호프만-라 로슈 아게 |
Type II anti-CD20 antibodies to reduce the formation of anti-drug antibodies
|
EP3389714A4
(en)
|
2015-12-14 |
2019-11-13 |
MacroGenics, Inc. |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
JP6991979B2
(en)
|
2016-02-05 |
2022-03-04 |
オリオニス バイオサイエンシズ ビーブイ |
CD8 binding substance
|
TW201730212A
(en)
|
2016-02-17 |
2017-09-01 |
宏觀基因股份有限公司 |
ROR1-binding molecules, and methods of use thereof
|
US11072666B2
(en)
|
2016-03-14 |
2021-07-27 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
CN109476756B
(en)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
Multi-specificity Fab fusion protein and application thereof
|
IL262396B2
(en)
|
2016-04-15 |
2023-09-01 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
IL301527A
(en)
|
2016-05-12 |
2023-05-01 |
Adicet Bio Inc |
METHODS FOR SELECTIVE EXPANSION OF ɣδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
|
TW201902512A
(en)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
treatment method
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
JP2019517539A
(en)
|
2016-06-07 |
2019-06-24 |
マクロジェニクス,インコーポレーテッド |
Combination therapy
|
WO2017218707A2
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
WO2017220989A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
CN109641049B
(en)
|
2016-06-21 |
2023-07-07 |
特尼奥生物股份有限公司 |
CD3 binding antibodies
|
CN116063545A
(en)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
Heterodimeric antibodies that bind somatostatin receptor 2
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
BR112019004873A2
(en)
|
2016-09-14 |
2019-06-11 |
Teneobio Inc |
cd3 binding antibodies
|
EP3526241A1
(en)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Il15/il15r heterodimeric fc-fusion proteins
|
US11242401B2
(en)
|
2016-10-21 |
2022-02-08 |
Biocon Limited |
Monoclonal antibody and a method of use for the treatment of lupus
|
US10610104B2
(en)
|
2016-12-07 |
2020-04-07 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
AU2017382251A1
(en)
|
2016-12-21 |
2019-07-11 |
Teneobio, Inc. |
Anti-BCMA heavy chain-only antibodies
|
EP3558368A4
(en)
|
2016-12-23 |
2020-12-30 |
MacroGenics, Inc. |
Adam9-binding molecules, and methods of use thereof
|
CN110121510A
(en)
|
2017-01-06 |
2019-08-13 |
克雷森多生物制剂有限公司 |
The single domain antibody of apoptosis (PD-1)
|
US11541076B2
(en)
*
|
2017-01-13 |
2023-01-03 |
Celdara Medical, Llc |
Chimeric antigen receptors targeting TIM-1
|
EP3574012A1
(en)
|
2017-01-27 |
2019-12-04 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
US11046768B2
(en)
|
2017-01-27 |
2021-06-29 |
Memorial Sloan Kettering Cancer Center |
Bispecific HER2 and CD3 binding molecules
|
WO2018144999A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
AU2018218324A1
(en)
|
2017-02-10 |
2019-08-22 |
Eutilex Co., Ltd. |
IFN-γ-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibody and uses thereof
|
WO2018183929A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
WO2018182422A1
(en)
|
2017-03-31 |
2018-10-04 |
Merus N.V. |
Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
|
CA3062825A1
(en)
*
|
2017-05-08 |
2018-11-15 |
Adimab, Llc |
Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
|
JP7381345B2
(en)
|
2017-05-16 |
2023-11-15 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
MANA body and usage
|
EP3630846A4
(en)
*
|
2017-05-31 |
2021-02-24 |
Carsgen Therapeutics Co., Ltd. |
Compositions and methods of cellular immunotherapy
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
CA3066353A1
(en)
*
|
2017-06-06 |
2018-12-13 |
The Brigham And Women's Hospital, Inc. |
Methods of suppressing microglial activation
|
CN117567624A
(en)
|
2017-06-20 |
2024-02-20 |
特纳奥尼股份有限公司 |
Heavy chain-only anti-BCMA antibodies
|
CN111132733A
(en)
|
2017-06-30 |
2020-05-08 |
Xencor股份有限公司 |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15R α and an antigen binding domain
|
HUE058233T2
(en)
|
2017-08-03 |
2022-07-28 |
Amgen Inc |
Interleukin-21 muteins and methods of treatment
|
TW201910354A
(en)
|
2017-08-09 |
2019-03-16 |
荷蘭商美勒斯公司 |
Antibodies that bind to epidermal growth factor receptor (EGFR) and cMET
|
EP3676294A4
(en)
*
|
2017-08-28 |
2021-12-22 |
Systimmune, Inc. |
Anti-cd3 antibodies and methods of making and using thereof
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
AU2018347607A1
(en)
|
2017-10-14 |
2020-03-26 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2019092452A1
(en)
*
|
2017-11-13 |
2019-05-16 |
Crescendo Biologics Limited |
Molecules that bind to cd137 and psma
|
EP3717008A1
(en)
|
2017-12-01 |
2020-10-07 |
Merus N.V. |
Use of bispecific antibody and il-15 for combination therapy
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
KR20200104364A
(en)
|
2017-12-27 |
2020-09-03 |
테네오바이오, 인코포레이티드 |
CD3-delta/epsilon heterodimer specific antibody
|
CR20200330A
(en)
|
2018-01-12 |
2020-12-23 |
Amgen Inc |
Anti-pd-1 antibodies and methods of treatment
|
GB201800649D0
(en)
|
2018-01-16 |
2018-02-28 |
Argenx Bvba |
CD70 Combination Therapy
|
TWI804572B
(en)
|
2018-02-09 |
2023-06-11 |
日商小野藥品工業股份有限公司 |
Bispecific antibody
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
WO2019204655A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
KR20210010862A
(en)
|
2018-04-18 |
2021-01-28 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-fusion protein and PD-1 targeting heterodimer fusion protein containing PD-1 antigen binding domain and uses thereof
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
JP2021532073A
(en)
|
2018-07-31 |
2021-11-25 |
アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dosing regimen for BCMA-CD3 bispecific antibodies
|
WO2020025792A1
(en)
|
2018-08-03 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Antibody constructs for cldn18.2 and cd3
|
MX2021002190A
(en)
|
2018-08-31 |
2021-05-14 |
Regeneron Pharma |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies.
|
BR112021005669A2
(en)
|
2018-09-28 |
2021-06-22 |
Amgen Inc. |
antibodies against soluble bcma
|
JP2022503959A
(en)
|
2018-10-03 |
2022-01-12 |
ゼンコア インコーポレイテッド |
IL-12 heterodimer FC-fusion protein
|
CN113166261A
(en)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7H3 single domain antibodies and therapeutic compositions thereof
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
WO2020076992A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
JP2022504822A
(en)
|
2018-10-11 |
2022-01-13 |
インヒブルクス インコーポレイテッド |
DLL3 single domain antibody and therapeutic composition thereof
|
JP2022512709A
(en)
|
2018-10-31 |
2022-02-07 |
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー |
Compositions and Methods for Treating Inflammatory and Autoimmune Diseases
|
US20230416385A1
(en)
|
2018-11-01 |
2023-12-28 |
Shandong New Time Pharmaceutical Co., Ltd. |
Bispecific antibody and use thereof
|
WO2020106750A1
(en)
|
2018-11-19 |
2020-05-28 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
TW202038958A
(en)
|
2018-12-18 |
2020-11-01 |
比利時商阿根思公司 |
Cd70 combination therapy
|
CN114344461A
(en)
|
2018-12-20 |
2022-04-15 |
美勒斯公司 |
CLEC12AxCD3 bispecific antibodies and methods for treating disease
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
TW202039578A
(en)
*
|
2019-03-29 |
2020-11-01 |
荷蘭商美勒斯公司 |
Cd3 binding molecules
|
KR102503349B1
(en)
|
2019-05-14 |
2023-02-23 |
프로벤션 바이오, 인코포레이티드 |
Methods and compositions for preventing type 1 diabetes
|
BR112021020426A2
(en)
*
|
2019-06-07 |
2022-03-08 |
Adimab Llc |
Engineered pH-dependent anti-cd3 antibodies and methods for their generation and use
|
CN114206927A
(en)
|
2019-06-14 |
2022-03-18 |
特尼奥生物股份有限公司 |
Multispecific heavy chain antibodies that bind to CD22 and CD3
|
WO2021006199A1
(en)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
|
CN114174343A
(en)
|
2019-07-30 |
2022-03-11 |
小野药品工业株式会社 |
Bispecific antibodies
|
WO2021035054A1
(en)
|
2019-08-20 |
2021-02-25 |
Precision Biosciences, Inc. |
Lymphodepletion dosing regimens for cellular immunotherapies
|
EP3819007A1
(en)
|
2019-11-11 |
2021-05-12 |
Amgen Research (Munich) GmbH |
Dosing regimen for anti-bcma agents
|
EP4058466A1
(en)
|
2019-11-13 |
2022-09-21 |
Amunix Pharmaceuticals, Inc. |
Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
CN115666704A
(en)
|
2019-12-13 |
2023-01-31 |
比奥拉治疗股份有限公司 |
Ingestible device for delivery of therapeutic agents to the gastrointestinal tract
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
US20210299235A1
(en)
*
|
2020-02-19 |
2021-09-30 |
Kai Yuan Xu |
Methods of treating polycystic kidney disease
|
WO2021207770A1
(en)
*
|
2020-04-11 |
2021-10-14 |
Northwestern University |
HUMANIZED ANTIBODY TARGETING THE TUMOR ASSOCIATED ANTIGEN IL13Ra2
|
JP2023526774A
(en)
|
2020-04-29 |
2023-06-23 |
テネオバイオ, インコーポレイテッド |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
JP2023527293A
(en)
|
2020-05-19 |
2023-06-28 |
アムジエン・インコーポレーテツド |
MAGEB2 binding construct
|
AU2021329378A1
(en)
|
2020-08-19 |
2023-03-23 |
Xencor, Inc. |
Anti-CD28 compositions
|
IL301926A
(en)
|
2020-11-06 |
2023-06-01 |
Amgen Inc |
Antigen binding domain with reduced clipping rate
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
EP4243936A1
(en)
|
2020-11-10 |
2023-09-20 |
Amgen Inc. |
Methods for administering a bcma x cd3 binding molecule
|
CA3209479A1
(en)
|
2021-02-03 |
2022-08-11 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
CN117157319A
(en)
|
2021-03-09 |
2023-12-01 |
Xencor股份有限公司 |
Heterodimeric antibodies that bind CD3 and CLDN6
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
EP4314075A2
(en)
*
|
2021-03-24 |
2024-02-07 |
Twist Bioscience Corporation |
Variant nucleic acid libraries for cd3
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
TW202317625A
(en)
|
2021-06-17 |
2023-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
Novel tri-specific binding molecules
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
KR102616360B1
(en)
*
|
2021-11-09 |
2023-12-27 |
재단법인 아산사회복지재단 |
Biomarker composition for diagnosing inflammatory myopathies
|
WO2023110918A1
(en)
|
2021-12-14 |
2023-06-22 |
Cdr-Life Ag |
Dual mhc-targeting t cell engager
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
TW202346337A
(en)
|
2022-03-29 |
2023-12-01 |
美商恩格姆生物製藥公司 |
Ilt3 and cd3 binding agents and methods of use thereof
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2024040127A2
(en)
*
|
2022-08-16 |
2024-02-22 |
Northwestern University |
Anti-tyrp1 bi-specific t cell engaging protein for treatment of tyrp1-expressing melanoma
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
US20240091262A1
(en)
|
2022-09-14 |
2024-03-21 |
Cdr-Life Ag |
Mage-a4 peptide dual t cell engagers
|